Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries LAWSUITS FILED AGAINST CCIV, CRMD and ITRM - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS By: Jakubowitz Law via AccessWire August 24, 2021 at 05:40 AM EDT NEW YORK, NY / ACCESSWIRE / August 24, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.Churchill Capital Corp IV (NYSE:CCIV)CONTACT JAKUBOWITZ ABOUT CCIV:https://claimyourloss.com/securities/churchill-capital-corp-iv-loss-submission-form/?id=18870&from=1Class Period : January 11, 2021 - February 22, 2021Lead Plaintiff Deadline : August 30, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Lucid was not prepared to deliver vehicles by spring of 2021; (2) Lucid was projecting a production of 557 vehicles in 2021 instead of the 6,000 vehicles touted in the run-up to the merger with Churchill; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.CorMedix Inc. (NASDAQ:CRMD)CONTACT JAKUBOWITZ ABOUT CRMD:https://claimyourloss.com/securities/cormedix-inc-loss-submission-form/?id=18870&from=1Class Period : July 8, 2020 - May 13, 2021Lead Plaintiff Deadline : September 20, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Iterum Therapeutics Plc (NASDAQ:ITRM)CONTACT JAKUBOWITZ ABOUT ITRM:https://claimyourloss.com/securities/iterum-therapeutics-plc-loss-submission-form/?id=18870&from=1Class Period : November 30, 2020 - July 23, 2021Lead Plaintiff Deadline : October 4, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:JAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (212) 867-4490F: (212) 537-5887SOURCE: Jakubowitz LawView source version on accesswire.com: https://www.accesswire.com/661101/LAWSUITS-FILED-AGAINST-CCIV-CRMD-and-ITRM--JAKUBOWITZ-LAW-PURSUES-SHAREHOLDERS-CLAIMS Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
LAWSUITS FILED AGAINST CCIV, CRMD and ITRM - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS By: Jakubowitz Law via AccessWire August 24, 2021 at 05:40 AM EDT NEW YORK, NY / ACCESSWIRE / August 24, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.Churchill Capital Corp IV (NYSE:CCIV)CONTACT JAKUBOWITZ ABOUT CCIV:https://claimyourloss.com/securities/churchill-capital-corp-iv-loss-submission-form/?id=18870&from=1Class Period : January 11, 2021 - February 22, 2021Lead Plaintiff Deadline : August 30, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Lucid was not prepared to deliver vehicles by spring of 2021; (2) Lucid was projecting a production of 557 vehicles in 2021 instead of the 6,000 vehicles touted in the run-up to the merger with Churchill; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.CorMedix Inc. (NASDAQ:CRMD)CONTACT JAKUBOWITZ ABOUT CRMD:https://claimyourloss.com/securities/cormedix-inc-loss-submission-form/?id=18870&from=1Class Period : July 8, 2020 - May 13, 2021Lead Plaintiff Deadline : September 20, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Iterum Therapeutics Plc (NASDAQ:ITRM)CONTACT JAKUBOWITZ ABOUT ITRM:https://claimyourloss.com/securities/iterum-therapeutics-plc-loss-submission-form/?id=18870&from=1Class Period : November 30, 2020 - July 23, 2021Lead Plaintiff Deadline : October 4, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:JAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (212) 867-4490F: (212) 537-5887SOURCE: Jakubowitz LawView source version on accesswire.com: https://www.accesswire.com/661101/LAWSUITS-FILED-AGAINST-CCIV-CRMD-and-ITRM--JAKUBOWITZ-LAW-PURSUES-SHAREHOLDERS-CLAIMS